Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516341 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure
Hard CopyAdd to Basket
Live Chat Live Help Software for Website

CD38 AS A PROGNOSTIC FACTOR IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA. Edition No. 1

VDM Publishing House, May 2010, Pages: 168


  Description  
   Authors   
    
    
    
     
  Enquire before Buying   
  Send to a Friend   

Chronic lymphocytic leukaemia follows an extremely variable clinical course with overall survival times ranging from months to decades, so there is a need to identify markers that may help to refine outcome prediction for these individuals. One of the most important molecular genetics parameters defining pathogenic and prognostic subgroups of Chronic lymphocytic leukaemia is the mutation status of the IgVH genes. CD38 expression has demonstrated a highly predictive prognostic value and can be used as a convenient and accurate predictor of IgVH gene mutational status. However, because IgVH gene mutational status assay is characterized by its technical complexity, high cost and needs for high level of expertise while CD38 percent expression can be determined more conveniently, rapidly and cheaper than IgVH gene mutational status, it offer the possibility of a substitute for IgVH gene mutations analysis. Moreover it may be the preferred adjunct to the current staging systems. Indeed, the results of this simple test should enable physicians to predict with considerable accuracy whether a patient is likely to have a favorable or unfavorable clinical course.



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds